Omeprazole and Cabazitaxel for the Treatment of Docetaxel- and Castration- Resistant Prostate Cancer

Inclusion Criteria

• Patients must have castrate refractory prostate cancer with prior docetaxel treatment which was used in the castrate refractory setting
• Cancer progression as defined by Prostate Cancer Working Group 3 (PCWG3), any type- PSA only, bone only +nodal, nodal only, visceral, or new lesions
• Age 18 or older
• Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
• Life expectancy of greater than 2 months
• Men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
• Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative)
• Absolute neutrophil count >= 1,200/mcL
• Platelets >= 75,000/mcL
• Total bilirubin = within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal
• Creatinine < 2.5 X institutional upper limit of normal

Exclusion Criteria

• Patients may not be receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to omeprazole or taxane therapy
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements